Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report [PDF]
, 2008 Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO ...
Amit Kumar Choudhury +10 more
core +3 more sources
Gastrointestinal stromal tumor (GIST) of the Treitz’s angle– a very rare cause of high bowel obstruction [PDF]
, 2016 Gastrointestinal stromal tumors (GIST) are somewhat rare gastrointestinal tumors - approximately 1% to 3% incidence, but they are the most common mesenchymal neoplasms of the gastrointestinal tract.
Georgescu, Lota Corina +3 more
core +3 more sources
American Journal of Experimental and Clinical Research, 2014 A unique case of a 50-year-old Japanese male with jejunal leiomyosarcoma (LMS) who subsequently developed gastrointestinal stromal tumor (GIST) and desmoid tumor (DT) during five years and six months after the initial surgery is reported. The patient was
Yuji Kurihara +2 more
doaj +2 more sources
Haematologica, 2011 Background Incubation of chronic myeloid leukemia cells in hypoxia inhibits growth and selects BCR/Abl-independent cells with stem cell properties which are refractory to imatinib-mesylate.
Serena Giuntoli +5 more
doaj +1 more source
The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines [PDF]
, 2012 Purpose Our aim was to evaluate the potential effect of imatinib mesylate (IM), a small molecule that specifically inhibits the tyrosine quinase receptors, on the proliferation and invasive abilities of two human retinoblastoma (Rb) cell lines ...
Antecka, E. +5 more
core +2 more sources
Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms
Cancer Science, EarlyView.In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley +1 more source
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Nandhini Gangadaran +9 more
wiley +1 more source
Toxics, 2021 Tyrosine kinase inhibitors (TKIs) are designed for targeted cancer therapy. The consumption of these drugs during the last 20 years has been constantly rising.
Tina Elersek +7 more
doaj +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [PDF]
, 2004 Imatinib mesylate (STI571), a potent tyrosine kinase inhibitor, is successfully used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. However, the intended chronic oral administration of imatinib may
Boersma, A.W.M. (Anton) +6 more
core +1 more source